309 related articles for article (PubMed ID: 37108955)
21. A 20-Year Antifungal Susceptibility Surveillance (From 1999 to 2019) for
Yang X; Chen W; Liang T; Tan J; Liu W; Sun Y; Wang Q; Xu H; Li L; Zhou Y; Wang Q; Wan Z; Song Y; Li R; Liu W
Front Microbiol; 2021; 12():680884. PubMed ID: 34367087
[TBL] [Abstract][Full Text] [Related]
22. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus.
Torres HA; Rivero GA; Lewis RE; Hachem R; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2003 May; 46(1):25-8. PubMed ID: 12742315
[TBL] [Abstract][Full Text] [Related]
23. Antifungal resistance in Aspergillus terreus: A current scenario.
Vahedi Shahandashti R; Lass-Flörl C
Fungal Genet Biol; 2019 Oct; 131():103247. PubMed ID: 31247322
[TBL] [Abstract][Full Text] [Related]
24. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
[TBL] [Abstract][Full Text] [Related]
25. Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China.
Zhang L; Wang X; Houbraken J; Mei H; Liao W; Hasimu H; Liu W; Deng S
Mycopathologia; 2020 Jun; 185(3):527-535. PubMed ID: 32346838
[TBL] [Abstract][Full Text] [Related]
26. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
Lass-Flörl C; Kofler G; Kropshofer G; Hermans J; Kreczy A; Dierich MP; Niederwieser D
J Antimicrob Chemother; 1998 Oct; 42(4):497-502. PubMed ID: 9818749
[TBL] [Abstract][Full Text] [Related]
27. Aspergillus tanneri sp. nov., a new pathogen that causes invasive disease refractory to antifungal therapy.
Sugui JA; Peterson SW; Clark LP; Nardone G; Folio L; Riedlinger G; Zerbe CS; Shea Y; Henderson CM; Zelazny AM; Holland SM; Kwon-Chung KJ
J Clin Microbiol; 2012 Oct; 50(10):3309-17. PubMed ID: 22855513
[TBL] [Abstract][Full Text] [Related]
28. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.
Gomez-Lopez A; Garcia-Effron G; Mellado E; Monzon A; Rodriguez-Tudela JL; Cuenca-Estrella M
Antimicrob Agents Chemother; 2003 Oct; 47(10):3085-8. PubMed ID: 14506013
[TBL] [Abstract][Full Text] [Related]
29. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility.
Mortensen KL; Johansen HK; Fuursted K; Knudsen JD; Gahrn-Hansen B; Jensen RH; Howard SJ; Arendrup MC
Eur J Clin Microbiol Infect Dis; 2011 Nov; 30(11):1355-63. PubMed ID: 21541671
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of oleylphosphocholine (OlPC) in vitro and in a mouse model of invasive aspergillosis.
Paulussen C; Boulet G; Bosschaerts T; Cos P; Fortin A; Maes L
Mycoses; 2015 Mar; 58(3):127-32. PubMed ID: 25590577
[TBL] [Abstract][Full Text] [Related]
32. Invasive Aspergillus infections in hematologic malignancy patients.
Perea S; Patterson TF
Semin Respir Infect; 2002 Jun; 17(2):99-105. PubMed ID: 12070828
[TBL] [Abstract][Full Text] [Related]
33. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
34. Drug-Resistant
De Francesco MA
Pathogens; 2023 Oct; 12(11):. PubMed ID: 38003770
[TBL] [Abstract][Full Text] [Related]
35. Environmental and clinical epidemiology of Aspergillus terreus: data from a prospective surveillance study.
Rüping MJ; Gerlach S; Fischer G; Lass-Flörl C; Hellmich M; Vehreschild JJ; Cornely OA
J Hosp Infect; 2011 Jul; 78(3):226-30. PubMed ID: 21440331
[TBL] [Abstract][Full Text] [Related]
36. [Invasive fungal infections in immunocompromised patients with focus on aspergillosis and its causative agents].
Paloušová D; Lengerová M; Volfová P; Bejdák P; Kocmanová I; Mayer J; Ráčil Z
Klin Mikrobiol Infekc Lek; 2012 Aug; 18(4):96-101. PubMed ID: 23172020
[TBL] [Abstract][Full Text] [Related]
37. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles.
Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
J Clin Microbiol; 2011 Feb; 49(2):586-90. PubMed ID: 21123534
[TBL] [Abstract][Full Text] [Related]
38. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species.
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2008 Aug; 46(8):2568-72. PubMed ID: 18562581
[TBL] [Abstract][Full Text] [Related]
39. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
40. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases].
Gürcan S; Tikveşli M; Eryildiz C; Evci C; Ener B
Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
